Sign in

CIK 0001815776

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

LENZ Therapeutics, Inc.

Sign in to watch
Ticker
LENZ
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
844867570
Phone
+1 858-925-7000
Business address
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH, CA, 92075
Former names
Graphite Bio, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$9,134,778
in 1 filing

Net −$9,134,778. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. RA CAPITAL MANAGEMENT, L.P. −$9.1M 10% owner sold 98% of stake
Date Insider Transaction Shares Price Value Owned after
2023-07-19 Jerel Davis Director Grant or award · Stock Option (right to buy) +20,000 20,000
2022-06-21 Jerel Davis Director Grant or award · Stock Option (right to buy) +20,000 20,000
2021-06-29 Jerel Davis Director Conversion +12,343,727 14,708,398
2021-06-29 Jerel Davis Director Conversion +1,527,719 1,527,719
2021-06-29 Jerel Davis Director Purchase +180,000 $17.00 $3.1M 1,707,719
2021-06-29 Jerel Davis Director Conversion · Series A Preferred Stock −30,019,945 0
2021-06-29 Jerel Davis Director Conversion · Series B Preferred Stock −3,715,415 0
2021-06-24 Jerel Davis Director Grant or award · Stock Option (right to buy) +40,000 40,000
2021-03-11 Jerel Davis Director Grant or award · Series B Preferred Stock +3,715,415 $5.06 $18.8M 3,715,415
2021-02-16 Jerel Davis Director Grant or award · Series A Preferred Stock +10,000,000 $1.00 $10.0M 30,019,945

Page 1 of 1 · 10 trades